Compare CRDO & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDO | IQV |
|---|---|---|
| Founded | 2008 | 1982 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 36.4B |
| IPO Year | 2022 | 2013 |
| Metric | CRDO | IQV |
|---|---|---|
| Price | $148.52 | $225.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 15 |
| Target Price | $179.91 | ★ $236.93 |
| AVG Volume (30 Days) | ★ 7.4M | 1.5M |
| Earning Date | 12-01-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.11 | ★ 7.30 |
| Revenue | $796,128,000.00 | ★ $15,904,000,000.00 |
| Revenue This Year | $127.02 | $6.14 |
| Revenue Next Year | $28.18 | $5.35 |
| P/E Ratio | $134.88 | ★ $30.72 |
| Revenue Growth | ★ 224.17 | 3.85 |
| 52 Week Low | $29.09 | $134.65 |
| 52 Week High | $213.80 | $234.30 |
| Indicator | CRDO | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 46.26 | 54.97 |
| Support Level | $132.76 | $219.91 |
| Resistance Level | $156.09 | $225.80 |
| Average True Range (ATR) | 9.87 | 5.04 |
| MACD | -1.88 | -0.55 |
| Stochastic Oscillator | 28.08 | 81.40 |
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.